| The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb AN Iness, J Felthousen, V Ananthapadmanabhan, F Sesay, S Saini, ... Oncogene 38 (7), 1080-1092, 2019 | 79 | 2019 |
| DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169 V R. Menon, V Ananthapadmanabhan, S Swanson, S Saini, F Sesay, ... Cell Cycle 18 (5), 531-551, 2019 | 40 | 2019 |
| Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma PC Lee, S Klaeger, PM Le, K Korthauer, J Cheng, ... The Journal of clinical investigation 132 (13), 2022 | 24 | 2022 |
| Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma V Ananthapadmanabhan, TC Frost, KM Soroko, A Knott, BJ Magliozzi, ... Jci Insight 7 (13), 2022 | 10 | 2022 |
| Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A V Ananthapadmanabhan, KH Shows, AJ Dickinson, L Litovchick Frontiers in Cell and Developmental Biology 11, 1277537, 2023 | 3 | 2023 |
| Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines V Ananthapadmanabhan, A Knott, KM Soroko, PC Gokhale, V Tirunagaru, ... Molecular Cancer Therapeutics 20 (12_Supplement), P203-P203, 2021 | 1 | 2021 |
| Proteomic and functional studies identify DCAF7 as major partner of DYRK1A V Anathapadmanabhan, S Swanson, S Saini, V Menon, L Litovchick Cancer Research 77 (13_Supplement), 343-343, 2017 | 1 | 2017 |
| 44 (PB032): The MDM2 degraders KTX-049 and KT-253 are highly active in wild-type TP53 (WT p53) Merkel cell carcinoma (MCC) Y Chutake, V Ananthapadmanabhan, A Teshager, P Gokhale, ... European Journal of Cancer 211, 114572, 2024 | | 2024 |
| Unraveling the mechanism of YAP toxicity in neuroendocrine solid tumors: Insights from Merkel cell carcinoma F Bahar, TC Frost, V Ananthapadmanabhan, JL Schnabel, M Thakuria, ... Cancer Research 84 (6_Supplement), 3042-3042, 2024 | | 2024 |
| The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC). V Ananthapadmanabhan, Y Chutake, J Filiatrault, S Schalm, A McDonald, ... Molecular Cancer Therapeutics 22 (12), 2023 | | 2023 |
| Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC) V Ananthapadmanabhan, TC Frost, KM Soroko, A Knott, B Magliozzi, ... Journal of Investigative Dermatology 142 (10), 2837, 2022 | | 2022 |
| Identification of novel viral class I-restricted peptides in Merkel cell carcinoma S Klaeger, PC Lee, S Rachimi, PM Le, VA Chea, IP Carulli, ... MOLECULAR & CELLULAR PROTEOMICS 21 (8), S45-S45, 2022 | | 2022 |
| James DeCaprio1, 2, 3 1. 2. 3. 4. 5 V Ananthapadmanabhan, TC Frost, KM Soroko, A Knott, BJ Magliozzi, ... JCI INSIGHT 7 (13), 2022 | | 2022 |
| Mass Spectrometry Based Identification of Novel HLA Class I Restricted Peptides in Merkel Cell Carcinoma S Rachimi, S Klaeger, PC Lee, PM Le, VA Chea, IP Carulli, ... The FASEB Journal 36, 2022 | | 2022 |
| Virally mediated mechanisms of HLA class I loss in Merkel cell carcinoma and implications for viral epitope presentation DB Keskin, PC Lee, S Klaeger, PM Le, K Korthauer, J Cheng, ... Journal of Investigative Dermatology 142 (10), 2838-2838, 2022 | | 2022 |
| Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53 (WT)) Merkel cell carcinoma (MCC) cell lines V Ananthapadmanabhan, A Knott, KM Soroko, PC Gokhale, V Tirunagaru, ... MOLECULAR CANCER THERAPEUTICS 20 (12), 2021 | | 2021 |
| Molecular Mechanisms of the DYRK1A-regulated DNA Repair P Bukina, V Ananthapadmanabhan | | 2020 |
| Characterization of the DYRK1A Protein-protein Interaction Network V Ananthapadmanabhan | | 2020 |
| The cell cycle gene regulatory DREAM complex is disrupted by oncogenic B-Myb AN Iness, V Ananthapadmanabhan, F Sesay, M Dozmorov, L Litovchick Cancer Research 78 (13_Supplement), 4288-4288, 2018 | | 2018 |
| The cell cycle gene regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb AN Iness, J Felthousen, V Ananthapadmanabhan, KZ Guiley, ... bioRxiv, 199539, 2017 | | 2017 |
